Italian startup Plumestars has announced via Twitter that it has received orphan drug status from the EMA for its amikacin dry powder inhaler for the treatment of P. aeruginosa infections in cystic fibrosis patients.
Here am amazing news: we got the orphan drug designation for our Amikacin dry powder! http://t.co/Ag3rCnXZAz
— PlumeStars (@PlumeStars) December 21, 2014
According to the company’s website, it is also developing a tobramycin DPI.
